title: Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users.
abstract: This cross-sectional study compared quality of life and side effects in 108 users of olanzapine or risperidone suffering schizophrenia and being attended at psychiatric ambulatory services in Rio Grande do Norte, Brazil. Economic, socio-demographic, anthropometric, biochemical, and hormonal variables were compared. The EuroQoL Five-Dimension Scale (EQ-5D) was used to evaluate quality of life, and side effects were assessed using the Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale and the Simpson-Angus Scale. Data were analysed using the χ(2) test and Student's t test, with a significance level of 5 %.The household incomes of approximately 80 % of patients were <2.0 minimum wages ($678). Anthropometric variables (waist circumference, hip circumference, weight, waist-to-hip ratio) and systolic and diastolic blood pressure were noted among male olanzapine users (all p < 0.05). EQ-5D scores showed that olanzapine use significantly impacted self-help ability (p < 0.001). Risperidone users had a mean quality-adjusted life year value of 1. Mean total Simpson-Angus Scale scores was 0.38 for olanzapine users and 0.11 for risperidone users (p < 0.02). Significant differences in UKU were observed for the following items: asthenia/lassitude/fatigue (higher among olanzapine users, p = 0.02), dystonia (higher among olanzapine users, p = 0.01), tremors (higher among olanzapine users, p = 0.03), gynecomastia (higher among risperidone users, p < 0.02), and ejaculatory dysfunction (higher among risperidone users, p < 0.02). Olanzapine users had impaired quality of life, which can be explained in part by adverse motor, biochemical, and hormonal effects characteristic of metabolic syndrome.
authors.affiliation: Postgraduate Programs in Public Health and Pharmaceutical Science, Department of Biophysics and Pharmacology, Federal University of Rio Grande Norte (UFRN), Natal, RN, Brazil. aurigena@ufrnet.br.
authors.forename: Aurigena Antunes
authors.initials: AA
authors.lastname: de Araújo
authors.affiliation: Postgraduate Program in Pharmaceutical Science, UFRN, Natal, RN, Brazil.
authors.forename: Susana Barbosa
authors.initials: SB
authors.lastname: Ribeiro
authors.affiliation: Postgraduate Program in Pharmaceutical Science, UFRN, Natal, RN, Brazil.
authors.forename: Ana Cely Souza
authors.initials: AC
authors.lastname: Dos Santos
authors.affiliation: Postgraduate Programs in Health Science and Pharmaceutical Science, Department of Clinical Analyses and Toxicological, Federal University of Rio Grande Norte (UFRN), Natal, RN, Brazil.
authors.forename: Telma Maria Araújo Moura
authors.initials: TM
authors.lastname: Lemos
authors.affiliation: Postgraduate Program in Health and Society, Department of Biophysics and Pharmacology, State University of Rio Grande Norte (UERN), Natal, RN, Brazil.|Postgraduate Programs in Biological Science, Federal University of Rio Grande Norte (UFRN), Natal, RN, Brazil.
authors.forename: Caroline Addison Xavier
authors.initials: CA
authors.lastname: Medeiros
authors.affiliation: Department of Biophysics and Pharmacology, Federal University of Rio Grande Norte (UFRN), Natal, RN, Brazil.
authors.forename: Gerlane Coelho Bernardo
authors.initials: GC
authors.lastname: Guerra
authors.affiliation: Postgraduate Program in Functional & Structural Biology and Health Science, Department of Morphology, UFRN, Natal, RN, Brazil.
authors.forename: Raimundo Fernandes
authors.initials: RF
authors.lastname: de Araújo Júnior
authors.affiliation: Acute Inpatient Unit of Psychiatry, Parc Sanitari Sant Joan de Deu, Barcelona, Spain.
authors.forename: Antoni
authors.initials: A
authors.lastname: Serrano-Blanco
authors.affiliation: Research and Innovation Unit, Parc Sanitari Sant Joan de Deu, Barcelona, Spain.
authors.forename: Maria
authors.initials: M
authors.lastname: Rubio-Valera
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects; D001569:Benzodiazepines / Q000009:adverse effects*; D001794:Blood Pressure / Q000187:drug effects; D001837:Body Weights and Measures; D003430:Cross-Sectional Studies; D064420:Drug-Related Side Effects and Adverse Reactions / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D011788:Quality of Life; D018967:Risperidone / Q000009:adverse effects*; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D018967:Risperidone; D000077152:Olanzapine
keywords: Olanzapine; Quality of life; Risperidone; Schizophrenia; Secondary effects